A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer

NCT05028504 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

86

Enrollment

OTHER

Sponsor class

Conditions

Gynecological Cancer

Interventions

DRUG: Penpulimab
DRUG: Anlotinib

Sponsor

Sichuan Cancer Hospital and Research Institute